Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study

Journal of the Medical Association of Thailand

Volumn 93, Issue 3, 2010, Pages 337-342

  Maneeton, Narong ^a   Thongkam, Annop ^b   Maneeton, Benchalak ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Suanprung Psychiatric Hospital   (Thailand)

Author keywords

Cognitive behavioral therapy; Fluoxetine; Major depressive disorder

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 77951904768     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jonas BS, Brody D, Roper M, Narrow WE. Prevalence of mood disorders in a national sample of young American adults. Soc Psychiatry Psychiatr Epidemiol 2003; 38: 618-24.
2. Geulayov G, Lipsitz J, Sabar R, Gross R. Depression in primary care in Israel. Isr Med Assoc J 2007; 9: 571-8.
3. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000; 157: 1925-32.
4. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry 2004; 4: 37.
5. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985; 46: 26-31.
6. Byerley WF, Reimherr FW, Wood DR, Grosser BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988; 8: 112-5.
7. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry 1984; 45: 414-9.
8. Haby MM, Donnelly M, Corry J, Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a metaregression of factors that may predict outcome. Aust N Z J Psychiatry 2006; 40: 9-19.
9. Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitivebehavioral therapy in depression: a meta-analytic approach. Clin Psychol Rev 2001; 21: 401-19.
10. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61: 714-9.
11. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807-20.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: APA; 1994.
13. Faramarzi M, Alipor A, Esmaelzadeh S, Kheirkhah F, Poladi K, Pash H. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. J Affect Disord 2008; 108: 159-64.
14. Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 2007; 161: 1026-34.
15. Kennard BD, Emslie GJ, Mayes TL, Nightingale-Teresi J, Nakonezny PA, Hughes JL, et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry 2008; 47: 1395-404.